MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: seminole who wrote (1065)	7/15/1998 2:33:00 PM
From: David Cathcart	Read Replies (1) of 1826

The conference call just completed and the comments were very encouraging, particularly regarding MGI 114. They have recently seen efficacy in an additional 4 - 6 patients. [I'm vague on the number because I first thought he said that had seen 6 efficacy cases recently, but later in the call it sounded like six was the total number. There were two early cases of efficacy.] Efficacy has been seen in colon, small cell lung and pancreatic cancers. They are beginning phase II at a 10.65 mg/m^2 dose level, with a provision to go higher in some patients. They reiterated that they are heading into phase II this month, and the total dosing regimen will last about four months per patient. The bad news on this is that we will have to wait until a regimen is complete, and the data analyzed, before we can expect to hear any results. I would think though that they should be able to tell us the number of patients enrolled and the types of cancer being treated. They remain confident that a European partner for MGI 114 will become a reality. Another interesting comment was that the increased Salagen numbers to are not due to "filling the pipeline" for Sjogren's syndrome, as would be the case with a drug that was totally new to the market. The pipeline was already stocked because of the earlier approval for head & neck. Everyday we get closer to sustained profitability, a European partner for MGI 114 and the likelihood of a major brokerage firm picking up coverage of MOGN. The future looks bright for MGI Pharma and the MOGN investment. We're shrinking tumors! David

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next